Conditions · Pancreatic cancer
Pancreatic cancer — clinical trials in Sweden
18 open options
- TRIALPHASE3RECRUITING
Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
Ferric carboxymaltose · Placebo — 1 site
- TRIALPHASE4RECRUITING
Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.
creon 35.000 Ph.U (R) · Best Standarard of Care — 4 sites
- TRIALPHASE2RECRUITING
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Autogene cevumeran · Atezolizumab · mFOLFIRINOX — 89 sites
- TRIALPHASE2 / PHASE3RECRUITING
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) — 2 sites
- TRIALNARECRUITING
Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not
Debulking surgery — 4 sites
- TRIALNARECRUITING
Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer
PALN resection — 6 sites
- TRIALPHASE3NOT_YET_RECRUITING
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
Oxaliplatin · Irinotecan · Folinic acid — 33 sites
- TRIALPHASE3RECRUITING
Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
FOLFIRINOX or gemcitabine-nab-paclitaxel · FOLFIRINOX or gemcitabine-nab-paclitaxel — 1 site
- TRIALNARECRUITING
Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors
Habib™ EndoHPB · ERCP — 1 site
- TRIALPHASE2RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Belzutifan — 84 sites
- TRIALPHASE1 / PHASE2RECRUITING
Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
Gemcitabine · Extroducer Infusion Catheter System — 1 site
- TRIALPHASE3RECRUITING
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
INCB161734 · Placebo · Investigator's choice of chemotherapy — 219 sites
- TRIALPHASE1RECRUITING
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
PF-08046050 · bevacizumab · 5-Fluorouracil (5-FU) — 48 sites
- TRIALPHASE1 / PHASE2RECRUITING
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles) · ANOC-002 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles) · ANOC-003 (TCR-T cells targeting KRAS G12D mutation presented by specific HLA alleles) — 10 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Risvutatug Rezetecan · Drug 1 · Drug 2 — 85 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
AZD9574 · Temozolomide (TMZ) · [11C]AZ1419 3391 — 32 sites
- TRIALPHASE1RECRUITING
PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI
68Ga-FAPI-46 · PET/CT — 1 site
- TRIALNANOT_YET_RECRUITING
Surgery for Liver Metastases From PDAC
Liver resection (ablation) — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.